Aktuellt
SENASTE
Redeye provides an update following SenzaGen’s Q3 2024 report. We argue that the report is solid as the company continues increasing its sales and keeping costs at reasonable levels. We only make minor adjustments to our estimates and look forward to the Q4 report, which historically has been strong.
LÄS MER
